دورية أكاديمية
[Thymoglobulin as induction treatment in kidney transplantants with low immunological risk: a Moroccan experience].
| العنوان: | [Thymoglobulin as induction treatment in kidney transplantants with low immunological risk: a Moroccan experience]. |
|---|---|
| عنوان ترانسليتريتد: | La thymoglobuline en traitement d’induction chez les transplantés rénaux à faible risque immunologique: une expérience marocaine. |
| المؤلفون: | Abouzid Z; Service de Néphrologie-Dialyse-Transplantation Rénale, Centre Hospitalier Universitaire Ibn Sina, Rabat, Maroc.; Service d´Urologie, Centre Hospitalier René Dubos, Pontoise, France., Amar MA; Service de Néphrologie-Dialyse-Transplantation Rénale, Centre Hospitalier Universitaire Ibn Sina, Rabat, Maroc.; Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc., Abdessater M; Service d´Urologie, Centre Hospitalier René Dubos, Pontoise, France., Alioubane M; Service de Néphrologie-Dialyse-Transplantation Rénale, Centre Hospitalier Universitaire Ibn Sina, Rabat, Maroc.; Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc., Benjaafar A; Service de Néphrologie-Dialyse-Transplantation Rénale, Centre Hospitalier Universitaire Ibn Sina, Rabat, Maroc.; Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc., Ouzeddoun N; Service de Néphrologie-Dialyse-Transplantation Rénale, Centre Hospitalier Universitaire Ibn Sina, Rabat, Maroc.; Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc., Benamar L; Service de Néphrologie-Dialyse-Transplantation Rénale, Centre Hospitalier Universitaire Ibn Sina, Rabat, Maroc.; Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc., Bayahia R; Service de Néphrologie-Dialyse-Transplantation Rénale, Centre Hospitalier Universitaire Ibn Sina, Rabat, Maroc.; Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc., Bouattar T; Service de Néphrologie-Dialyse-Transplantation Rénale, Centre Hospitalier Universitaire Ibn Sina, Rabat, Maroc.; Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc. |
| المصدر: | The Pan African medical journal [Pan Afr Med J] 2022 Feb 17; Vol. 41, pp. 138. Date of Electronic Publication: 2022 Feb 17 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | French |
| بيانات الدورية: | Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet ISSN: 1937-8688 (Electronic) NLM ISO Abbreviation: Pan Afr Med J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Kampala, Uganda : African Field Epidemiology Network |
| مواضيع طبية MeSH: | Cytomegalovirus Infections*/drug therapy , Graft Rejection*/prevention & control, Antilymphocyte Serum ; Female ; Graft Survival ; Humans ; Immunosuppressive Agents/therapeutic use ; Infant, Newborn ; Kidney ; Male ; Retrospective Studies |
| مستخلص: | Introduction: Thymoglobulin® is a polyclonal antibody indicated for induction treatment in kidney transplantation. The purpose of this study is to estimate the effectiveness of Thymoglobulin® as induction treatment in kidney transplant patients with low immune risk. Methods: we conducted a retrospective study between January 2012 and September 2017. Patients with low immunological risk, defined as the absence of previous transplantation and donor-specific antibodies (DSA), were included and received Thymoglobulin® induction therapy. Demographic and clinical characteristics, biological parameters and post-renal transplant complications were studied. Results: we enrolled 55 kidney transplant patients with an average follow-up period of 38 ± 16 months. The average age of patients was 39,1 ± 12,1 years with a male predominance (58.2%). No patient had DSA prior to transplant. Cumulative dose of Thymoglobulin® was 4,26 ± 0,87 mg/kg, with an average duration of 5 ± 0,82 days. Lymphocyte depletion was maximal on the first day of infusion. Three patients had delayed graft function, at least one episode of bacterial infection in 56,4% of patients, 7 cases of CMV infections (12,7%) and 2 cases of CMV disease (3,6%). Graft survival rate was calculated for all patients with an average serum creatinine of 11,7 ± 3,6 mg/l during the last visit. Conclusion: although it is not indicated for first line treatment in patients with low immunological risk, Thymoglobulin® can nevertheless be prescribed at a lower dose, with similar efficacy and without exposure to a higher risk of rejection. Competing Interests: Les auteurs ne déclarent aucun conflit d´intérêts. (Copyright: Zineb Abouzid et al.) |
| References: | Transplantation. 2004 Aug 27;78(4):584-90. (PMID: 15446319) PLoS One. 2014 Aug 11;9(8):e104408. (PMID: 25111080) Transplantation. 2000 Nov 15;70(9):1352-9. (PMID: 11087152) Transplantation. 2002 May 15;73(9):1514-8. (PMID: 12023634) Am J Kidney Dis. 2010 Jan;55(1):141-3. (PMID: 19628314) Transplant Proc. 2009 Oct;41(8):3323-5. (PMID: 19857742) Transplantation. 2001 Sep 27;72(6):1050-5. (PMID: 11579299) Am J Transplant. 2010 Sep;10(9):2132-2141. (PMID: 20883548) Transplantation. 2001 Dec 27;72(12):1915-9. (PMID: 11773888) Transplant Proc. 2001 Nov-Dec;33(7-8):3192-3. (PMID: 11750368) N Engl J Med. 2011 May 19;364(20):1909-19. (PMID: 21591943) Transplantation. 2003 Mar 27;75(6):844-51. (PMID: 12660513) Transplant Proc. 2000 Mar;32(2):396-7. (PMID: 10715452) Transpl Immunol. 2012 Jun;26(4):186-90. (PMID: 22410573) Transpl Int. 2002 Sep;15(8):393-6. (PMID: 12221457) Transplantation. 2006 May 15;81(9):1227-33. (PMID: 16699447) Clin Transplant. 2006 Jul-Aug;20(4):401-9. (PMID: 16842513) Transplantation. 2003 Sep 15;76(5):798-802. (PMID: 14501856) Transplant Proc. 2011 Mar;43(2):458-61. (PMID: 21440733) Transplantation. 2000 Mar 15;69(5):799-805. (PMID: 10755529) Pharmacotherapy. 2006 Dec;26(12):1771-83. (PMID: 17125438) Transplant Proc. 1998 Sep;30(6):2859-60. (PMID: 9745599) Transplant Proc. 2010 Jun;42(5):1395-400. (PMID: 20620442) Transpl Int. 2006 Jun;19(6):446-57. (PMID: 16771865) Transplantation. 1998 Jul 15;66(1):29-37. (PMID: 9679818) J Heart Lung Transplant. 2007 May;26(5):504-10. (PMID: 17449421) Clin Transplant. 2003 Dec;17(6):539-45. (PMID: 14756271) Nephrol Dial Transplant. 2002 Jul;17(7):1304-9. (PMID: 12105256) Transplantation. 2008 Aug 27;86(4):521-8. (PMID: 18724220) Am J Transplant. 2002 Jan;2(1):48-56. (PMID: 12095056) Transplantation. 2007 Sep 27;84(6):715-21. (PMID: 17893604) Clin Transplant. 2008 Jan-Feb;22(1):41-9. (PMID: 18217904) Cochrane Database Syst Rev. 2010 Jan 20;(1):CD003897. (PMID: 20091551) J Heart Lung Transplant. 2007 Jul;26(7):693-9. (PMID: 17613399) N Engl J Med. 2006 Nov 9;355(19):1967-77. (PMID: 17093248) Clin J Am Soc Nephrol. 2015 Jun 5;10(6):923-5. (PMID: 25979977) |
| فهرسة مساهمة: | Keywords: Thymoglobulin; induction treatment; renal transplantation |
| المشرفين على المادة: | 0 (Antilymphocyte Serum) 0 (Immunosuppressive Agents) D7RD81HE4W (thymoglobulin) |
| تواريخ الأحداث: | Date Created: 20220506 Date Completed: 20220509 Latest Revision: 20230916 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9034569 |
| DOI: | 10.11604/pamj.2022.41.138.23091 |
| PMID: | 35519161 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1937-8688 |
|---|---|
| DOI: | 10.11604/pamj.2022.41.138.23091 |